Assembly Biosciences to Host Research and Development Day on Wednesday, June 20, 2018
INDIANAPOLIS and SAN FRANCISCO,
Company management will present the scientific rationale for core inhibitors to become a potential backbone to a curative regimen for patients with chronic HBV, the limitations of current standard-of-care for chronic HBV, Assembly’s clinical results and development plans for its core inhibitor candidates, and the potential impact of curative therapy on HBV market dynamics.
Epidemiology of the disease, medical need and strategies for improving cure rates will be discussed by two physician guest speakers:
Douglas T. Dieterich, MD—Director, Institute of Liver Medicine, Professor of Medicine, Division of Liver Disease, Department of Medicine, Icahn School of Medicineat Mount Sinai, New York, NY.
- Jörg Petersen, MD, PhD —Professor of Medicine and Head of the Liver Unit at the
IFI Institute for Interdisciplinary Medicineat the Asklepios Klinik St.George, University of Hamburg, Germany.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at assemblybio.com. The archived webcast will be available on Assembly’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
Institutional investors and equity analysts seeking information or registration for the live event in
About Assembly Biosciences
The information in this press release contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of core inhibitors, including ABI-H0731, and the timing of Assembly’s planned clinical studies. Certain forward-looking statements may be identified by reference to a future period or by use of forward-looking terminology such as “will,” “expected,” and “potential.” Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Assembly are more fully detailed under the heading “Risk Factors” in Assembly’s Quarterly Report on Form 10-Q for the quarter ended
Source: Assembly Biosciences